Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...
Mylan CEO Heather Bresch. Source: Forbes Shares of Mylan ( MYL ) to were under pressure last week after news surfaced that patients and pharmacists were struggling to get their hands on the company's emergency allergic reaction treatment, Epipen: A persistent shortage of Mylan NV's E...
On July 9 th , Sandoz, a division of Novartis ( NVS ), announced the long-awaited US retail launch of SYMJEPI in both adult and pediatric doses. SYMJEPI is single-dose, pre-filled syringe drug/device combination for emergency treatment of Type 1 allergic reactions, including anaphylaxis th...
NESS ZIONA, Israel, July 15, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term lease agreement at the Har-Hotzvim Hi-Tech Park in Jerusalem for the establishment of a new st...
Insider buying is usually a bullish sign while insider selling is seen as bearish. For instance, there were a lot of executive options exercised with some of them sold at $13.44 on May 7th on Amneal Pharmaceuticals, Inc. ( AMRX ) a couple of days before the company was to release Q1 results: ...
Source: Pixabay Introduction Since I started writing for SA in 2015, I've been dedicated to tracking the performance of my ideas as best I can. Because of the way the stock market works, I've noticed that there is often a disconnect between the power of a narrative behind an investment...
Walgreens (NASDAQ: WBA ) announces the availability of privately held kaléo's AUVI-q (epinephrine injection, USP) 0.10 mg auto-injector at its retail pharmacies nationwide. This formulation is the only one approved in the U.S. for treating emergency allergic reactions in infants and t...
Mylan N.V. ( MYL -5.2% ) slips on below-average volume on the heels of a Bloomberg report that patients and pharmacists are still scrambling to obtain emergency allergic reaction treatment EPiPen (epinephrine injection), in short supply for over a year now. More news on: Mylan N.V., Ad...
HERTFORDSHIRE, England and PITTSBURGH and SYDNEY , July 8, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) and medical device manufacturer Atomo Diagnostics today announced that the Mylan HIV Self Test , a handheld in vitro HIV...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...